Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke (SPS3)
Source: View publication →
In patients with recent lacunar strokes, long-term dual antiplatelet therapy with clopidogrel and aspirin did not reduce recurrent stroke risk but significantly increased major hemorrhage and all-cause mortality compared to aspirin alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
The SPS3 trial definitively established that long-term dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is contraindicated for the secondary prevention of lacunar strokes. Because DAPT provided no efficacy benefit while substantially increasing major bleeding and mortality, antiplatelet monotherapy (e.g., aspirin or clopidogrel alone) remains the standard of care for long-term secondary prevention in this population. The findings underscore the critical difference between using DAPT for short-term secondary prevention in acute minor stroke (later proven beneficial) versus long-term DAPT in small-vessel stroke.
Historical Context
Lacunar strokes represent approximately 25% of ischemic strokes and result from unique small-vessel arteriopathy. Prior to SPS3, the MATCH trial (2004) demonstrated that adding aspirin to clopidogrel did not benefit a broad population of stroke patients but increased bleeding. However, it remained hypothesized that the distinct microvascular pathology of lacunar stroke might respond differently to intense platelet inhibition. The SPS3 trial explicitly tested this in a rigorously defined, MRI-confirmed lacunar stroke cohort. The results firmly closed the door on long-term DAPT for lacunar strokes. Later trials, such as CHANCE (2013) and POINT (2018), would refine stroke prevention strategies by showing that DAPT is highly effective and safe only if initiated within 12-24 hours of a minor stroke and limited to a short duration (21 to 90 days).
Guided Discussion
High-yield insights from every perspective
How does the underlying pathophysiology of a lacunar stroke differ from a large vessel cortical stroke, and why might this explain the lack of efficacy of dual antiplatelet therapy in the SPS3 trial?
Key Response
Lacunar strokes are typically caused by lipohyalinosis or microatheroma of deep penetrating arteries rather than large atherothrombotic emboli. DAPT targets platelet aggregation, which is highly beneficial in plaque rupture seen in large vessels, but may not address the lipohyalinosis mechanism of small vessel disease, explaining the lack of benefit and excess bleeding risk.
The SPS3 trial showed harm with DAPT in lacunar stroke, but the CHANCE and POINT trials showed benefit for DAPT. How do you reconcile these findings when deciding on the duration and type of antiplatelet therapy for a patient presenting two weeks after a lacunar stroke?
Key Response
CHANCE and POINT evaluated short-term DAPT (21-90 days) started within 12-24 hours for minor stroke/TIA to prevent early recurrence. SPS3 evaluated long-term DAPT (average 3.4 years) started weeks to months after a lacunar stroke. Thus, for a patient post-lacunar stroke, long-term DAPT is contraindicated due to increased bleeding and mortality risk.
Given the increased rate of major hemorrhage and all-cause mortality in the SPS3 DAPT arm, how should the presence of cerebral microbleeds on MRI influence your antiplatelet choice in patients with severe cerebral small vessel disease?
Key Response
Lacunar strokes manifest cerebral small vessel disease (SVD), which often coexists with hypertensive microangiopathy or cerebral amyloid angiopathy, visible as microbleeds on MRI. The high bleeding risk in SPS3 highlights the fragility of these small vessels. Fellows must weigh the burden of microbleeds when prescribing antiplatelet therapy, recognizing that aggressive antiplatelet regimens in severe SVD may tip the scale toward fatal intracerebral hemorrhage.
The SPS3 trial was halted early due to an unexpected increase in all-cause mortality in the DAPT group. How does this finding reshape our broader cognitive approach to secondary prevention, particularly the trap of assuming more aggressive medical therapy yields better outcomes?
Key Response
Historically, physicians assumed combining pathways (COX inhibition plus P2Y12 inhibition) would inherently reduce ischemic events. SPS3 serves as a profound teaching point that in certain pathologies like small vessel disease, aggressive combinations not only fail to prevent the target disease but cause lethal collateral damage, underscoring the necessity of tailoring therapy to the specific stroke mechanism.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The SPS3 trial utilized a 2x2 factorial design, randomizing patients to both antiplatelet regimens and two target blood pressure ranges. How does early termination of one arm (the antiplatelet arm) due to safety concerns impact the statistical power and interpretation of the remaining factorial component regarding blood pressure targets?
Key Response
In a 2x2 factorial design, early termination of one intervention can introduce informative censoring or reduce the anticipated number of events for the ongoing arm, potentially underpowering the remaining blood pressure question. It also complicates the assessment of interaction effects between blood pressure lowering and antiplatelet therapy, requiring careful statistical adjustment.
A critical threat to validity in small subcortical stroke trials is diagnostic misclassification. As an editor reviewing this manuscript, how would you scrutinize the MRI inclusion criteria and the delay between stroke onset and randomization (up to 180 days) as potential confounders for the observed lack of efficacy?
Key Response
Lacunar strokes are difficult to classify perfectly without stringent MRI criteria, as small embolic infarcts can mimic them. Furthermore, randomizing patients up to 6 months post-stroke misses the acute high-risk window for recurrence where DAPT is most effective. A reviewer would flag whether the lack of efficacy was partly due to missing the highest-risk temporal window and diluting the cohort.
Based on the SPS3 trial outcomes, how should AHA/ASA guidelines specifically grade the recommendation against long-term dual antiplatelet therapy in patients with a history of lacunar stroke, and how does this carve out an explicit exception compared to coronary artery disease guidelines?
Key Response
Current AHA/ASA guidelines strongly recommend single antiplatelet therapy for secondary prevention of non-cardioembolic stroke. SPS3 provides Class III (Harm) Level B-R evidence against the use of long-term clopidogrel plus aspirin specifically for lacunar strokes. The committee must explicitly differentiate this from cardiology guidelines, ensuring practitioners do not inappropriately extrapolate CAD long-term DAPT guidelines to small vessel cerebrovascular disease.
Clinical Landscape
Noteworthy Related Trials
MATCH Trial
Tested
Clopidogrel 75mg plus Aspirin 75mg daily
Population
Patients with recent ischemic stroke or TIA and additional vascular risk factors
Comparator
Clopidogrel 75mg daily plus placebo
Endpoint
Composite of ischemic stroke, MI, vascular death, or rehospitalization for acute ischemia
CHANCE Trial
Tested
Clopidogrel plus Aspirin for 21 days, followed by clopidogrel alone
Population
Patients with acute minor ischemic stroke or high-risk TIA
Comparator
Aspirin alone
Endpoint
Stroke (ischemic or hemorrhagic) at 90 days
POINT Trial
Tested
Clopidogrel plus Aspirin for 90 days
Population
Patients with minor ischemic stroke or high-risk TIA
Comparator
Aspirin alone
Endpoint
Composite of ischemic stroke, MI, or death from ischemic vascular causes at 90 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis